Abstract
Introduction
Artemisinin is a natural product of the plant Artemisia annua L. Reduction of artemisinin yields the more active dihydroartemisinin (DHA), a compound which is thermally less stable [1] . DHA can be further converted to different derivatives, including, for example, artesunate and artemether, which are generally referred to as artemisinins. Artemisinins are widely known for their potent anti-malarial activity [2] , but also have efficacy in the treatment of several protozoal and schistosomal infections [3, 4] . Indeed, artemisinin-like compounds exhibit a wide spectrum of biological activities, including, for example, antiangiogenic, anti-tumorigenic and even anti-viral, all of which are medically relevant [5] [6] [7] [8] [9] [10] [11] .
Insights into the mechanisms of action of artemisinins are increasingly being gained. The anti-tumorigenic activity of the drug is believed to be partly due to iron-dependent generation of reactive oxygen species (ROS) [8] , as well as alkylation of proteins and DNA [12, 13] . The underlying molecular mechanisms by which artemisinins suppress angiogenesis, which in turn, likely contributes to the anti-tumour activities, are less clear. Nonetheless, direct effects on angiogenesis and lymphangiogenesis have been described. Artemisinins inhibit endothelial cell proliferation, cell migration and endothelial tube formation, at least partly by inducing apoptosis. They also interfere with synthesis of vascular endothelial growth factors [14] [15] [16] [17] [18] [19] [20] [21] [22] , possibly via suppression of hypoxia inducible factor activation [23] .
In spite of its therapeutic utility in treating malaria, resistant strains of the malaria parasites are emerging, mostly in western Cambodia, where treatment failure rates after combination therapy have exceeded 10% [24] . The mechanisms of resistance are largely unknown, but may replicate some of those that become active in cancer cells as they develop chemoresistance. These include, among others, mutations in target proteins, resistance to apoptosis and increased drug efflux via transporters [25] . Interestingly, the latter mechanism is known to be used by parasites to enhance the clearance of drugs, and the multidrug resistance-conferring ATP-binding cassette (ABC) transporter, P-glycoprotein (P-gp) [ 
26] has been implicated. Increased expression of ABC transporters such as P-gp may also enable tumour endothelial cells to escape from anti-angiogenic treatment. Because artemisinin-like compounds are generally well tolerated, with potentially wide clinical applications beyond malaria, it is important to identify alternative forms that do not induce host resistance.
In this report, we synthesized several novel artemisinin-like compounds, and tested their in vitro cytotoxic effects, their capacity to alter P-gp function and finally their in vivo anti-angiogenic properties. Our strategy was based on the generally accepted concept that DHA, a breakdown product of artesunate (see structures, Fig. 1 (4) [27] , deoxoartemisinin (3) [28] , 10-dihydroartemisinyl acetate (7) [29] , compound 5a synthesized by a modified procedure, NaOH/H2O2 were used as oxidizing agents [30] , 10-dihydroartemisinyl benzoate [13, (29) with small modification, instead of benzoylchloride, the benzoic anhydride was used with catalytic amount of 4-(dimethylamino)-pyridine (DMAP)] were prepared as previously described. 
Synthesis of 10-(2-butyloxy) dihydroartemisinin (15)
Boron trifluoride-diethyl ether (3 ml 
(m, 1 H, H-9), 2.9 (t, 2H), 3.1 (t, 2H), 4.56 (d, J ϭ 10.0 Hz, 1 H, H-10), 5.31 (s, 1 H, H-12); EIMS (m/z) 344.5 (MϩH)
ϩ . 
XTT cytotoxicity assay

Isolation of porcine brain capillary endothelial cells (PBCECs)
PBCECs were isolated from porcine brains as reported [35] . [29] . The ether and amine (Fig. 3) were made by reacting DHA with a Levis acid forming an oxonium ion [38] (Fig. 4) . A similar reaction was previously reported [39] . Figure 5, [38, 39] .
Results
Synthesis of compounds
Cytotoxicity (XTT assay)
Calcein assays
As a next step, we analysed whether the transport of calcein was affected by artemisinin and its derivatives to answer the question, whether artemisinin-like compounds act as P-gp inhibitors. As can be seen in
Inhibition of blood brain barrier function
The inhibitory potential of artemisinin derivatives towards P-gp expressed in porcine capillaries was analysed by confocal microscopy. Figure 6 shows control capillaries, where luminal localized P-gp effluxes a fluorescent P-gp substrate [40] , [41] . (Fig. 6, bottom row) .
N--(4-nitrobenzofurazan-7-yl)-d-Lys8 (NBD)-cyclosporin A (NBD-CSA) back into the capillary lumen (green). Exposure to both 8 and 15 resulted in an almost empty lumen, indicating that the P-gp substrate NBD-CSA accumulated in the endothelial cells, indicating inhibition of P-gp (Fig. 6). Luminal P-gp was inhibited by a well-known selective P-gylcoprotein inhibitor, PSC-833 (data not shown)
The inhibition of luminal P-gp in porcine brain capillaries by seven artemisinin derivatives was quantified by fluorospectrometry
Inhibition of angiogenesis in vivo
Eight compounds (4, 7, 8, 9, 10, 11, 12 and 15) were compared to artesunate for their anti-angiogenic potential using an in vivo zebrafish embryo model system (Fig. 7 and 
Inhibition of VEGF-induced HUVEC proliferation
To further test the anti-angiogenic potential of our novel compounds, we assayed proliferation and survival of HUVECs treated with VEGF and two compounds that were very active in the zebrafish model. Artemisinin and VEGF alone served as control and reference compound (Fig. 8) In the treatment of cancer, drug resistance remains a major impediment to success. One well-characterized pathway that promotes drug resistance is the P-gp transfer system [42, 43] .
Its relevance in clinical oncology is well known. For example, P-gp is expressed at the blood brain barrier, thereby hindering the delivery of functionally active anti-tumour drugs to the central nervous system [44] [45] [46] .
Unfortunately, overcoming drug resistance by using compounds, such as verapamil or PSC-833 that interfere with P-gp function, has not successfully entered the clinic due to excess toxicity [47] . Notably, artemisinin and artesunate are well tolerated in clinical malaria studies [48] [10] . They do not exhibit cross-resistance in cell lines selected for vincristine or epirubicin resistance [49] , nor to cell lines selected for methotrexate or hydroxyurea [9] . Furthermore [5, 9, 50, 51] . This result has been confirmed in another cell line panel with 39 cell lines of different tumour origin [52] and investigation using cell lines derived from Kaposi sarcoma [19] , medularry thyroid carcinoma [53] and non-Hodgkin lymphoma [54] . All these data indicate that artemisinin-type compounds may be active in otherwise drug-resistant cancer cells.
In the present study, we found that some artemisinin derivatives exert collateral sensitivity, i.e. doxorubicin-resistant P-gp overexpressing CEM/ADR5000 cells were more sensitive to these compounds than the parental wild-type CCRF-CEM cells. Collateral sensitivity is a well-known phenomenon in multidrug-resistance cancer cells for more than three decades [54] and led to the development of treatment strategies with compounds that selectively kill multidrug resistant cancer cells [56, 57] from ADP by oxidative phosphorylation generates ROS [58] . ROS production may lead to increased cell killing. This view is conceivable with the fact that cell with high P-gp expression exhibit higher collateral sensitivity than cells with low P-gp levels. It is well known that Artemisinin derivatives produce ROS leading to apoptosis [59, 60] . Hence, it can be speculated that some of our derivatives produced more ROS than others leading to higher degrees of collateral sensitivity.
In addition to collateral sensitivity, the question about possible synergistic effects in combination treatments can be asked. Indeed, we previously found that the combination of artesunate increased the apoptosis-inducing effects of doxorubicin in CEM/ADR5000 leukaemia cells [59] . A comparable result has also been reported for Plasmodium falciparum, doxorubicin and artemisinin showed synergistic interaction as compared to each drug alone [61] .
Furthermore [18] [19] [20] [21] [22] .
Overall, our findings demonstrate that these synthesized artemisinin-like compounds are not only endowed with different 
